|
Prometnaya G.A., Batyushin M.M., Bondarenko N.B.
Association of hyperuricemia with metabolism in patients with chronic kidney disease of 5th stage on hemodialysis
|
№3 / 2019
|
|
Polyakova I.V., Borovkova N.Yu., Maslova T.I., Maksimova I.Yu., Zubova S.Yu., Solov’yanova E.N.
View of the vascular stiffness and cardiovascular risk in patients with chronic glomerulonephritis
|
№2 / 2019
|
|
Kazakova I.A., Ievlev Y.N.
Electrophoretic mobility of erythrocytes in patients with chronic renal disease of 5th dialysis stage with different level of arterial pressure
|
№2 / 2019
|
|
Vyalkina N.A., Klyashev S.M., Vyalkina Y.A., Mezhonov E.M., Klyasheva Y.M.
Peculiarities of the daily profile of arterial pressure and its impact on the outcomes of patients with chronic kidneys disease, receiving program hemodialysis
|
№2 / 2019
|
|
NADEEVA R.A., SIGITOVA O.N., KIM T.Yu., KAMASHEVA G.R., KISELYOVA T.A.
Clinical recommendations for correction of carbohydrate metabolism and sugar reducing therapy in patients with type 2 diabetes and chronic renal disease
|
№2 / 2019
|
|
Muchtarov T.A., Skvortsov V.V.
Modern marker of renal dysfunction
|
№8 / 2017
|
|
A.G. Evdokimova, Е.V. Коvаlеnко, V.V. Evdokimov, К.I. Теblоеv, I.А. Shvetsova
Features of use of angiotensin receptor blockers in clinical practice (focus on candesartan)
|
№6 / 2017
|
|
A.Yu. Zakharova , A.V. Gordeev, Z.Yu. Mutovina, L.P. Ananyeva, Ye.A. Galushko
Systemic scleroderma and chronic kidney disease
|
№4 / 2017
|
|
A.G. Yevdokimova, Ye.V. Kovalenko, V.V. Yevdokimov, O.A. Shuiskaya
Potentials for the use of diuretic therapy in the clinic of internal diseases
|
№2 / 2017
|
|
A.V. Melekhov
Atrial fibrillation and chronic kidney disease: correction of treatment
|
№2 / 2017
|
Русский
